Axitinib is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign Out
